Two selective HDAC6 inhibitors, ACY-1215 (Ricolinostat), and ACY-241 (Citarinostat) are currently being studied in clinical trials for hematologic and non-hematologic cancers [130]. The gene discussed is HDAC6; the disease is hematopoietic and lymphoid cell neoplasm.